The Technical Analyst
TG Therapeutics Inc [TGTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
TG Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.32% $14.10
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 177.34 mill |
| EPS: | 0.0900 |
| P/E: | 156.67 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 154.42 mill |
| Avg Daily Volume: | 3.52 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 156.67 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 26.65x |
| Company: PE 156.67 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 13.34 - 14.87 ( +/- 5.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
| 2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
| 2024-02-14 | Power Sean A | Buy | 0 | |
| 2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
| 2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
| INSIDER POWER |
|---|
| 83.72 |
| Last 94 transactions |
| Buy: 12 977 390 | Sell: 1 920 924 |
Forecast:
16:00 - $14.13
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.13
Forecast 2: 16:00 - $14.13
Forecast 3: 16:00 - $14.13
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.10 (2.32% ) |
| Volume | 2.24 mill |
| Avg. Vol. | 3.52 mill |
| % of Avg. Vol | 63.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TGTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.58 | N/A | Active |
|---|
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Latest Press Releases
2024-04-18 07:30:00 - Press Release
Tg Therapeutics Announces Additional Data Presentations For Briumvi® (ublituximab-xiiy) In Multiple Sclerosis At The American Academy Of Neurology 2024 Annual Meeting
New york, april 18, 2024 (globe newswire) -- tg therapeutics, inc. (nasdaq: tgtx), today announced two additional data presentations from the ultimate i & ii phase 3 trials evaluating briumvi® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (rms), at the 2024 american academy of neurology (aan) annual meeting, being held in denver, colorado. links to the data presented yesterday are included below.
2024-04-18 07:00:00 - Press Release
Tg Therapeutics Awarded National Contract By The Department Of Veterans Affairs For Briumvi As The Preferred Anti-cd20 For Relapsing Forms Of Multiple Sclerosis
New york, april 18, 2024 (globe newswire) -- tg therapeutics, inc. (nasdaq: tgtx), announced that it has been awarded a national contract with the department of veterans affairs (va) for briumvi® (ublituximab-xiiy) to be the preferred agent listed on the va national formulary for anti-cd20 antibody indications for patients with relapsing forms of multiple sclerosis (rms).
2024-04-15 07:30:00 - Press Release
Tg Therapeutics Announces Presentation Of Data For Briumvi® (ublituximab-xiiy) In Multiple Sclerosis At The American Academy Of Neurology 2024 Annual Meeting
New york, april 15, 2024 (globe newswire) -- tg therapeutics, inc. (nasdaq: tgtx), today announced the presentation of data from the ultimate i & ii phase 3 trials evaluating briumvi® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (rms), at the 2024 american academy of neurology (aan) annual meeting, being held in denver, colorado. a link to the data presented yesterday is included below. two additional presentations will be shared on wednesday april 17, 2024.
2024-03-22 03:30:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Tg Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / march 22, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of tg therapeutics, inc. ("tg therapeutics" or "the company") (nasdaq:tgtx) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-03-08 07:30:00 - Press Release
Tg Therapeutics Announces Schedule Of Data Presentations For Briumvi® (ublituximab) In Multiple Sclerosis At The American Academy Of Neurology 2024 Annual Meeting
New york, march 08, 2024 (globe newswire) -- tg therapeutics, inc. (nasdaq: tgtx), today announced the schedule of data presentations highlighting data from the ultimate i & ii phase 3 trials evaluating briumvi® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (rms), at the upcoming american academy of neurology 2024 annual meeting, being held april 13 - 18, 2024, in dever, colorado. abstracts are now available online and can be accessed on the aan meeting website at https://www.aan.com/msa/public/events/index/49. details of the upcoming presentations are outlined below.
Latest News
2024-04-12 18:17:47 - Seeking Alpha
TG Therapeutics: BRIUMVI Development Could Lead To Great Results
TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023, with positive market feedback and significant revenue. The company has strong barriers to entry and patent protection for BRIUMVI, allowing for potential growth in 2024 and 2025.
2024-02-28 13:14:12 - Seeking Alpha
TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
2024-02-28 09:11:14 - Zacks Investment Research
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.39 per share a year ago.
2024-02-23 07:30:00 - GlobeNewsWire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET
2024-02-20 11:06:49 - Zacks Investment Research
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-10 10:00:05 - Seeking Alpha
TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance and the expense guidance suggest the company should become cash flow positive and profitable in the second half of the year. The company plans to start human trials for a subcutaneous version of Briumvi, aiming to improve convenience and compete with other treatments.
2024-01-10 09:28:08 - Invezz
TG Therapeutics stock popped 11% on Wednesday: here's why
Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened 11% up on Wednesday after the biopharmaceutical firm said it sees a meaningful increase in its revenue from Briumvi this year. TG Therapeutics issues outlook for 2024 The Nasdaq-listed firm is expected to have concluded 2023 with about $89 million in U.S.
2024-01-10 07:36:00 - Market Watch
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
TG Therapeutics Inc.'s stock TGTX, -1.36% rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. DTIL, +10.10% to acquire a worldwide license to that company's Azercabtagene Zapreleucel, or azer-cel, a CAR T cell therapy program for autoimmune diseases and other non-oncology indications. “Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024,” TG Therapeutics said in a statement.
2023-12-06 09:55:29 - Invezz
TGTX stock price Has the TG Therapeutics train left the station?
TG Therapeutics (NASDAQ: TGTX) stock price continued its recovery after the company published strong financial results. The shares jumped to the psychologically important level of $15, its highest point since April 23rd.
2023-11-28 04:36:07 - Seeking Alpha
TG Therapeutics: Trying To Fill The Gap Back To $20
TG Therapeutics' Q3'23 net sales of Briumvi of $25.1M seemed to impress the market. Q3'23 sales of Briumvi were aided by J-code availability and increases in payor coverage. Q4'23 sales are hard to predict but given the size of the anti-CD20 market in multiple sclerosis patients, it is unlikely Briumvi sales will top out soon.